Estudo randomizado fase 1/2 | CoronaVac é bem tolerada, segura e induz forte resposta humoral em crianças e adolescentes de 3 a 17 anos de idade.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Comentário convidado: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases

Comentário no Twitter

NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc

— The Lancet (@TheLancet) June 28, 2021